Cure8 research brief
Monogenic causes (especially IL-10RA mutations) are common in infant-onset IBD and are linked to more severe disease and higher mortality; early genetic testing and consideration of HSCT may change prognosis.
Pediatric gastroenterologists, geneticists, clinicians treating infant-onset IBD, parents/caregivers of infants diagnosed with IBD, and researchers studying monogenic IBD.
The researchers reviewed clinical, genetic, treatment, and outcome data for 98 IO-IBD patients (median onset ~4 months). Of 77 children who had genetic testing, 39 had definite monogenic mutations; 33 of those involved IL-10RA. Children with monogenic IO-IBD had more severe disease and higher mortality.
The report highlights that IL-10RA–related IO-IBD often presents with Crohn's-like features including higher rates of perianal disease and penetrating behavior. Six children with IL-10RA mutations who underwent HSCT survived during follow-up, whereas mortality was substantially higher among those who did not receive HSCT.
The authors recommend routine IL-10RA genetic testing for all children with IO-IBD and early evaluation for HSCT when indicated.
This is a retrospective single-center study from Beijing Children’s Hospital with genetic testing performed in a subset (77/98). The Structured content depth is an abstract; findings are based on the authors' reported cohort and follow-up. HSCT outcomes described are from this observational series and do not substitute for individualized clinical decision-making.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study provides region-specific pediatric IBD data from the Philippines, highlighting prevalence of very-early-onset disease, perianal involvement in Crohn's, and factors (diagnostic delay, wasting, pancolitis)...
A cross‑trust histopathology MDT helped reclassify diagnoses in a substantial proportion of discussed paediatric IBD cases and occasionally changed management or transition planning, which could affect treatment...
This registry will track long-term safety and clinical outcomes in children with IBD, with a focus on infliximab (an anti‑TNF biologic) versus non‑biologic therapies. Long follow-up could help identify uncommon or late...
